Anti-Parkinson Drugs by Dr.Shikha Parmar 

Glad to hear that

Use of NMDA antagonists in Parkinson’s Disease (PD) (1) NMDA antagonists block abnormal glutamate signals seen in the pathogenesis of Parkinson’s disease. (2) subthreshold doses of NMDA antagonists cause enhanced release of striatal dopamine and (3) Parkinson’s Disease models suggest that NMDA antagonism may protect nigral neurons. It has been found that NMDA antagonism improves PD symptoms, is neuroprotective and prevent PD progression by inhibition of glutamatergic-mediated excitotoxicity. Reference: Vanle Brigitte et al; NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease; Transl Psychiatry; 2018; Vol 8: page 117. Hope this clears your question

Thanks for watching and liking the video